Carmat

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Small modular reactors – why governments and tech giants are embracing SMRs

Digital assets: Unlocking opportunities in listed blockchain equities

Hybrid Air Vehicles – Military options advance

Audiovisual

Latest

The Diverse Income Trust in 60 seconds

Waymap – executive interview

Herantis Pharma – executive interview

About Edison

About Edison

Careers

Carmat (PAR: ALCAR)

Latest Insights

Carmat: Edison Open House Healthcare 2022

Carmat — Implantation momentum

Carmat – Edison Open House interview

Carmat – executive interview with Stéphane Piat

Sector

Research

Carmat — Carmat obtains clearance to resume pivotal study

Carmat — Update 1 December 2016

Executive Interview – Carmat

Carmat — Update 15 July 2016

Carmat — Update 5 May 2016

Further insights

Total Artificial Hearts

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time